ArticleScientific reports2026
tRF-34-P4R8YP9LON4VHM may serve as a promising potential diagnostic biomarker for hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatocellular carcinoma represents one of the most common and fatal malignancies worldwide, with early diagnosis being critical for enhancing patient survival rates. Traditional tumor biomarkers have limitations, as serum biomarker levels remain normal in certain patients, thus constraining diagnostic accuracy. Previous researches have elucidated that tRNA-derived small RNAs (tsRNAs) exert a critical function as regulators in the pathogenesis of malignant tumors. Nevertheless, the clinical relevance of circulating tsRNAs in HCC remains largely unclear. Consequently, this research aimed to examine the possible application of a newly identified tsRNA (tRF-34-P4R8YP9LON4VHM) for auxiliary diagnosis, disease surveillance, and prognostic evaluation of HCC. tRF-34-P4R8YP9LON4VHM was detected through high-throughput sequencing, and its serum concentration was quantified using qRT-PCR. Methodological evaluation demonstrated that qRT-PCR for detecting serum tRF-34-P4R8YP9LON4VHM exhibited excellent stability, reproducibility, and specificity. Serum level of this biomarker were markedly upregulated in HCC patients compared to hepatitis patients and the healthy, and it decreased significantly following surgical resection. Moreover, elevated serum level was strongly associated with advanced TNM stage, lymph node metastasis, and tumor differentiation. Our data suggest that serum tRF-34-P4R8YP9LON4VHM is a promising auxiliary diagnostic biomarker for HCC and may further function as a valuable indicator for disease monitoring and prognostic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.